Severe Group A Streptococcus Infections in Paris, France, 2018-2023
IGASI
IGASI
Sponsor study identifier
observational
269
1 country
1
Study Start
May 13, 2024
Actual (reported)Primary Completion
August 19, 2024
Actual (reported)Study Completion
August 19, 2024
Actual (reported)Streptococcus pyogenes, commonly referred to as Group A Streptococcus (GAS), has the ability to induce a diverse range of illnesses. In several European countries and the United States, a notable surge in invasive GAS (iGAS) infections has been documented since mid-2022. This sharp increase contrasts with the gradual rise in iGAS incidence observed among children over the past three decades. As demonstrated for several viral infections, the recent upturn in iGAS infections is potentially linked to the relaxation of mitigation measures implemented during the COVID-19 pandemic, such as face mask usage and school closures. Since November 2022, concerns have been raised by French public health authorities regarding the rise in levels of iGAS infections, and an unexpected increase in pediatric severe GAS infections was reported in a French single-center study. However, this study ended in December 2022 and could only explore short-term trends. The Necker - Enfants malades Hospital in Paris, France, represents an excellent opportunity to examine the impact of the COVID-19 pandemic and the associated non-pharmaceutical interventions on the incidence of severe GAS infections, during, and after the pandemic. This study aims to investigate trends of severe GAS infection incidence in children in the Paris area over the course of the COVID-19 pandemic.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
August 19, 2024
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 19, 2024
Actual (reported)March 7, 2024
Actual (reported)May 13, 2024
Actual (reported)August 19, 2024
Actual (reported)August 19, 2024
Actual (reported)Monthly incidence of severe Group A Streptococcus (GAS) infections per 1000 pediatric hospital admissions
The monthly incidence of severe group A streptococcal infections per 1000 pediatric hospital admissions. Two specific breakpoints in the data will be used: March 2020, marking the first lockdown, and March 2022, marking the point when mask-wearing in schools was no longer mandatory. This will allow to define four distinct periods for analysis: * January 2018 to March 2020 (pre-pandemic period), * April 2020 to March 2022 (early pandemic period), * April 2022 to September 2023 (late pandemic period), and * May 2023 to December 2023 (post pandemic period).
6 years
Age of children age with group A Streptococcus (GAS) infections
6 years
Proportion of children needing surgical intervention for the management of GAS infection
6 years
Proportion of cases admitted in the PICU for GAS infection
6 years
Proportion of deaths from GAS infection
6 years
Hospital length of stay for the management of GAS infection
6 years
All consecutive children under the age of 18 years with community-acquired or healthcare-associated severe Group A Streptococcus (GAS) infections admitted to Necker hospital between January 1, 2018, and December 31, 2023. Among GAS infections, invasive and probable invasive GAS illnesses will be distinguish. "Invasive GAS" infection will be defined as: isolation by culture or polymerase chain reaction of GAS from a normally sterile site; or isolation of GAS from a sterile or non-sterile site accompanied by necrotizing fasciitis or streptococcal toxic shock syndrome. "Probable invasive" GAS will be defined as acute infections with GAS isolated from a non-sterile site, which includes sputum, otorhinolaryngology surgical specimens (mastoiditis, ethmoiditis, pharyngeal abscess) accompanied with one or more of the following severity criteria:intravenous antibiotics;surgery; and/or admission to the pediatric intensive care unit.
Collection of data from the patient's medical file (electronic health record). The identification of eligible cases will be conducted through an examination of the hospital's electronic microbiology database. Subsequently, the complete hospital record(s) of each patient will be used to extract a pre-defined set of variables required for data analysis.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
All consecutive children under the age of 18 years with community-acquired or healthcare-associated severe Group A Streptococcus (GAS) infections admitted to Necker-Enfants Malades hospital between January 1, 2018, and December 31, 2023.
Hôpital Necker-Enfants Malades
Paris, 75015, France
Flamant A, Faury H, Luscan R, Couloigner V, Pouletty M, Bustarret O, Chappuy H, Gaume M, Drummond D, Pinhas Y, Toubiana J, Ferroni A, Cohen JF. Severe Group A Streptococcus Infections in Children During and After the COVID-19 Pandemic: An Interrupted Time-series Analysis in Paris, France, 2018-2023. Pediatr Infect Dis J. 2025 Oct 1;44(10):973-978. doi: 10.1097/INF.0000000000004872. Epub 2025 May 28.
Jérémie Cohen
Assistance Publique - Hôpitaux de Paris
Alix Flamant, M.D.
Assistance Publique - Hôpitaux de Paris
269 participants (actual enrollment reported by the registry).
First Submitted
February 19, 2024
First Posted
March 7, 2024
Study Start
May 13, 2024
Actual (reported)Initiating Pediatric Palliative Care in ACT Group 4
Contact the study team to confirm eligibility.
Primary Completion
August 19, 2024
Actual (reported)Study Completion
August 19, 2024
Actual (reported)Last Updated
September 15, 2025
Record last verified: 2025-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: